alexa A Dendritic Cell-Targeted Vaccine Loaded with Glyceraldehyde-3-Phosphate Dehydrogenase Peptides Proposed for Individuals at High Risk of Listeriosis
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A Dendritic Cell-Targeted Vaccine Loaded with Glyceraldehyde-3-Phosphate Dehydrogenase Peptides Proposed for Individuals at High Risk of Listeriosis

Ricardo Calderon-Gonzalez1, Elisabet Frande-Cabanes1, Raquel Tobes2, Eduardo Pareja2, Lidia Alaez-Alvarez1 and Carmen Alvarez-Dominguez1 *

1Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain

2Information Technologies Research Group, Era7 Bioinformatics, Granada, Spain

*Corresponding Author:
Carmen Alvarez-Dominguez
Grupo de Genómica, Proteómica y Vacunas. Instituto de Investigación Marqués de Valdecilla (IDIVAL)
Laboratorio 124, Edificio IDIVAL, Avda
Cardenal Herrera Oria, s/n. 39011 Santander, Cantabria, Spain
Tel: 34-942315515/74104
Fax: +34-942-315517
E-mail: [email protected]

Received date: December 15, 2014; Accepted date: January 16, 2015; Published date: January 20, 2015

Citation: Calderon-Gonzalez G, Frande-Cabanes E, Tobes R, Pareja E, Alaez-Alvarez L, et al. (2015) A Dendritic Cell-Targeted Vaccine Loaded with Glyceraldehyde-3-Phosphate Dehydrogenase Peptides Proposed for Individuals at High Risk of Listeriosis . J Vaccines Vaccin 6:266. doi: 10.4172/2157-7560.1000266

Copyright: © 2015 Calderon-Gonzalez R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: Individuals at risk of Listeria infection lacked vaccines to prevent the development of severe  listeriosis symptoms. Here, we identify the best epitopes from Listeria proteins GAPDH and LLO for an optimal DC vaccine candidate to protect against individuals high susceptible to listeriosis.

Methods: We vaccinated high susceptible Balb/c and low susceptible C57BL/6 mice with a single dose of DC-LLO91-99, DC-LLO189-200, DC-LLO190-201, DC-LLO189-201, DC-LLO296-304, DC-GAPDH1-15 or DC-GAPDH1-22 vaccines. CFU in spleens, predictions of DC- peptide binding to MHC-I and MHC-II and analysis of Th1 immune responses were used to assess vaccine efficiency.

Results: DC-GAPDH1-22 and DC-GAPDH1-15 vaccines with intermediate binding epitopes to MHC-I and weak binders to MHC-II, provided maximal protection in Listeria susceptible and resistant mice. DC-LLO91-99 vaccine with a strong binding epitope to MHC-I follows protection in both mice strains. DC-LLO296-304 vaccine conferred protection only in resistant mice and DC-LLO190-201, DC-LLO189-200 and DC-LLO189-201 vaccines with binding epitopes to MHC-II, lacked protection properties. Maximal protection in listeriosis correlated with increased splenic CD8α+ DC, enhanced IL-12 production and high frequencies of CD8+ and CD4+ producing IFN- T cells in both mice strains.

Discussion: Maximal protection against listeriosis in susceptible and resistant mice is only achieved with DC-GAPDH1-22 and DC-GAPDH1-15 vaccines, able to activate simultaneously CD4+ and CD8+ T cells as they include binding epitopes to both, MHC-I and MHC-II. CD8+ T cell activation seemed predominant as DC-LLO91-99 and DC-LLO296-304 vaccines that exclusively activate CD8+ T cells in both mice strains conferred significant listeriosis protection. In this regard, DC-LLO189-201, DC-LLO189-200 or DC-LLO190-201 vaccines that activated CD4+ T cells caused no protection at all. We observed that a combination of several MHC-I and at least one MHC-II binding epitopes in a single peptide provided the highest listeriosis protection.

Conclusion: DC-GAPDH1-22 and DC-GAPDH1-15 vaccines might protect against human listeriosis in high susceptible immune-compromise patients.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords